Physician profile
Jamie Martinez
NPI 1700467933
$1,294.41
in general payments reported to CMS, 2019-2025
14 companies · $86.88 in 2025
The $86.88 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $450 · 2022: $544 · 2024: $214 · 2025: $86.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $156.25 | 2024 | Vyloy, Veozah |
| Amgen INC. | $145.82 | 2022 | |
| Exelixis INC. | $135.00 | 2021 | |
| Lilly USA, LLC | $133.46 | 2021 | |
| Janssen Biotech, INC. | $121.38 | 2021-2022 | |
| Eisai INC. | $120.38 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $118.08 | 2021 | |
| Abbvie INC. | $114.59 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $103.30 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $44.89 | 2022 | |
| Genentech USA, INC. | $29.97 | 2025 | Itovebi |
| Helsinn Therapeutics (U.S.), INC. | $27.11 | 2022 | |
| Merck Sharp & Dohme LLC | $24.10 | 2022 | |
| Karyopharm Therapeutics INC. | $20.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.